Update
$NeuroSense Therapeutics(NRSN.US$ NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
6 MINUTES AGO, 8:30 AM EST
VIA PR NEWSWIRE
• PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS
• Standard ALS Measure ALSFRS-R already demonstrated a statistically significant effect of PrimeC on slowing down disease progression
• Further analysis of PARADIGM is on track with neurofilament results expected in Q1 and TDP-43 and ProstaglandinJ2 biomarkers expected in the first half of 2024
6 MINUTES AGO, 8:30 AM EST
VIA PR NEWSWIRE
• PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS
• Standard ALS Measure ALSFRS-R already demonstrated a statistically significant effect of PrimeC on slowing down disease progression
• Further analysis of PARADIGM is on track with neurofilament results expected in Q1 and TDP-43 and ProstaglandinJ2 biomarkers expected in the first half of 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
